Artal Group S.A. Madrigal Pharmaceuticals, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$171.37 - $283.23 $18.9 Million - $31.3 Million	110,507 New	110,507 $29.5 Million
Q3 2019 Nov 14, 2019	SELL	$84.4 - $106.53 $2.95 Million - $3.73 Million	-35,000 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$103.48 - $143.84 $3.62 Million - $5.03 Million	-35,000 Reduced 50.0%	35,000 $4.38 Million
Q4 2018 Feb 11, 2019	BUY	$94.77 - $215.54 $1.9 Million - $4.31 Million	20,000 Added 40.0%	70,000 $7.89 Million
Q2 2018 Aug 10, 2018	BUY	$101.55 - $313.9 $507,750 - $1.57 Million	5,000 Added 11.11%	50,000 $14 Million
Q1 2018 May 10, 2018	BUY	$93.35 - $149.04 $4.2 Million - $6.71 Million	45,000 New	45,000 $5.26 Million

296

21.9M

819K

644K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.52B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.